Coronavirus-treatment-updates
NICE guidelines: The holistic assessment, investigation, and management approach suggested by NICE are outlined here.Pulmonary Symptoms ManagementInvestigations:Pulmonary symptoms are common during long covid. NICE recommends that breathlessness may be investigated using an exercise tolerance test suited to the person’s ability, for example the one...
The LANCET: Published on
December, 2022Oral
antivirals have been an important addition to efforts to minimise adverse
COVID-19 outcomes in individuals at high risk.The earlier first
trial of molnupiravir showed only a 30% reduction of hospitalisations and
deaths with molnupiravir compared with placebo. Subsequent observational
studies in...
The New England Journal of MedicineMolnupiravir is an orally
administered form of a potent ribonucleoside analog that inhibits the
replication of SARS-CoV-2. For nonhospitalized, unvaccinated adults with
mild-to-moderate COVID-19 and at least one risk factor for severe disease,
molnupiravir reduces the risk for hospitalization or death, accordi...
The U.S. Food and Drug
Administration approved the emergency use of the molnupiravir pill for the
treatment of mild-to-moderate coronavirus disease 2019 in nonhospitalized adult patients with positive
results of direct SARS-CoV-2 viral testing who are at high risk for progressing
to severe COVID-19, including hospitalization or death.Does molnu...
Omicron driving spike in new Covid-19 cases in Bangladesh
recently and expected to rise in coming days according to health officials. The Covid-19 positivity rate in Bangladesh has reached the
highest-ever 33.37% in last week. The health authorities recorded 15,440 new infections after
testing 46,268 samples across the country. The latest figure...
The National Institute for Health and Care Excellence (NICE) GuidanceManaging cough Recommendations· Encourage patient
with cough to avoid lying on their backs, if possible, because this may make
coughing less effective.· Be aware
that older people or those with comorbidities, frailty, impaired immunity or a
reduced ability to cough...
Nirmatrelvir and Ritonavir is the
first oral agent authorized by FDA (Emergency Use Authorization) for treatment
of mild-to-moderate coronavirus disease in adults and
pediatric patients.
In a randomized, double-blind,
placebo-controlled clinical trial, Nirmatrelvir and Ritonavir significantly
reduced the proportion of people with COVI...
The U.S. Food and Drug
Administration (USFDA) issued an emergency use authorization (EUA) for a new
monoclonal antibody for the treatment of COVID-19 that retains activity against
the omicron variant.
The EUA for Bebtelovimab is for the treatment of mild to moderate COVID-19 in
adults and pediatric patients (12 years of age and older we...
The COVID-19 Treatment Guidelines:
On December 22 and 23, 2021, the
Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs)
that allow 2 new oral antiviral agents to be used in this patient population:
ritonavir-boosted nirmatrelvir and molnupiravir.
Ritonavir-Boosted Nirmatrelvir
Nirmatrelvir is an orally bi...
The New England Journal of Medicine
Infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and illness
with the associated coronavirus disease 2019 (Covid-19) continue to threaten
global health.
Persons
with particular characteristics such as older age, current smoking, or
underlying clinical conditions such as...
JAMA Internal Medicine
Ivermectin
treatment during early illness does not prevent progression to severe disease
for high-risk patients with mild-to-moderate COVID-19, according to a study
published online Feb. 18 in JAMA
Internal Medicine.
An in
vitro study demonstrated inhibitory effects of ivermectin against SARS-CoV-2.
Although s...
American College of Physicians (ACP) Journals: Annals of Internal
Medicine
Nirmatrelvir–ritonavir (NMV/r) is use in high-risk patients with
mild to moderate COVID-19 who are likely to be receiving other medications. NMV/r
administered within three days of symptom onset reduced the risk of COVID-19
related hospitalization and death from a...
